de Goldman Sachs Acadia Pharmaceuticals ACAD Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 65.3 M | Comprar |
2,580,115
+1,022,311
| +66% | +USD 22.5 M | 0.01% | 1581 |
|
|
2026
Q1 | USD 34.7 M | Vender |
1,557,804
-12,247
| -0.8% | -USD 293 k | ﹤0.01% | 1897 |
|
|
2025
Q4 | USD 41.9 M | Vender |
1,570,051
-532,399
| -25% | -USD 12.7 M | 0.01% | 1661 |
|
|
2025
Q3 | USD 44.9 M | Comprar |
2,102,450
+633,962
| +43% | +USD 15 M | 0.01% | 1501 |
|
|
2025
Q2 | USD 31.7 M | Vender |
1,468,488
-710,282
| -33% | -USD 13.2 M | ﹤0.01% | 1705 |
|
|
2025
Q1 | USD 36.2 M | Vender |
2,178,770
-701,694
| -24% | -USD 12.7 M | 0.01% | 1471 |
|
|
2024
Q4 | USD 52.9 M | Comprar |
2,880,464
+1,121,605
| +64% | +USD 18.1 M | 0.01% | 1244 |
|
|
2024
Q3 | USD 27.1 M | Comprar |
1,758,859
+417,915
| +31% | +USD 6.97 M | ﹤0.01% | 1783 |
|
|
2024
Q2 | USD 21.8 M | Comprar |
1,340,944
+613,039
| +84% | +USD 9.9 M | ﹤0.01% | 1823 |
|
|
2024
Q1 | USD 13.5 M | Vender |
727,905
-76,265
| -9% | -USD 1.89 M | ﹤0.01% | 2188 |
|
|
2023
Q4 | USD 25.2 M | Comprar |
804,170
+85,545
| +12% | +USD 2.04 M | ﹤0.01% | 1691 |
|
|
2023
Q3 | USD 15 M | Vender |
718,625
-554,799
| -44% | -USD 15.1 M | ﹤0.01% | 2033 |
|
|
2023
Q2 | USD 30.5 M | Comprar |
1,273,424
+293,686
| +30% | +USD 6.53 M | 0.01% | 1492 |
|
|
2023
Q1 | USD 18.4 M | Vender |
979,738
-10,885
| -1% | -USD 207 k | ﹤0.01% | 1880 |
|
|
2022
Q4 | USD 15.8 M | Vender |
990,623
-189,775
| -16% | -USD 2.97 M | ﹤0.01% | 2168 |
|
|
2022
Q3 | USD 19.3 M | Comprar |
1,180,398
+122,904
| +12% | +USD 1.99 M | ﹤0.01% | 1900 |
|
|
2022
Q2 | USD 14.9 M | Vender |
1,057,494
-46,883
| -4% | -USD 875 k | ﹤0.01% | 2137 |
|
|
2022
Q1 | USD 26.7 M | Vender |
1,104,377
-77,546
| -7% | -USD 1.88 M | 0.01% | 1815 |
|
|
2021
Q4 | USD 27.6 M | Comprar |
1,181,923
+355,077
| +43% | +USD 7.14 M | 0.01% | 1837 |
|
|
2021
Q3 | USD 13.7 M | Comprar |
826,846
+265,531
| +47% | +USD 5.12 M | ﹤0.01% | 2413 |
|
|
2021
Q2 | USD 13.7 M | Vender |
561,315
-480,934
| -46% | -USD 10.9 M | ﹤0.01% | 2397 |
|
|
2021
Q1 | USD 26.9 M | Comprar |
1,042,249
+31,159
| +3% | +USD 1.37 M | 0.01% | 1682 |
|
|
2020
Q4 | USD 54.1 M | Comprar |
1,011,090
+51,023
| +5% | +USD 2.53 M | 0.01% | 1071 |
|
|
2020
Q3 | USD 39.6 M | Vender |
960,067
-140,479
| -13% | -USD 6.07 M | 0.01% | 1178 |
|
|
2020
Q2 | USD 53.3 M | Vender |
1,100,546
-295,931
| -21% | -USD 14.2 M | 0.02% | 905 |
|
|
2020
Q1 | USD 59 M | Comprar |
1,396,477
+142,920
| +11% | +USD 5.89 M | 0.02% | 760 |
|
|
2019
Q4 | USD 53.6 M | Comprar |
1,253,557
+2,181
| +0.2% | +USD 94.9 k | 0.01% | 1090 |
|
|
2019
Q3 | USD 45 M | Vender |
1,251,376
-377,611
| -23% | -USD 11.5 M | 0.01% | 1177 |
|
|
2019
Q2 | USD 43.5 M | Vender |
1,628,987
-304,158
| -16% | -USD 7.77 M | 0.01% | 1232 |
|
|
2019
Q1 | USD 51.9 M | Vender |
1,933,145
-418,767
| -18% | -USD 9.8 M | 0.02% | 1093 |
|
|
2018
Q4 | USD 38 M | Comprar |
2,351,912
+1,074,005
| +84% | +USD 20.9 M | 0.01% | 1291 |
|
|
2018
Q3 | USD 26.5 M | Comprar |
1,277,907
+535,024
| +72% | +USD 8.42 M | 0.01% | 1711 |
|
|
2018
Q2 | USD 11.3 M | Vender |
742,883
-540,163
| -42% | -USD 9.6 M | ﹤0.01% | 2306 |
|
|
2018
Q1 | USD 28.8 M | Comprar |
1,283,046
+92,122
| +8% | +USD 2.55 M | 0.01% | 1550 |
|
|
2017
Q4 | USD 35.9 M | Vender |
1,190,924
-629,354
| -35% | -USD 20.1 M | 0.01% | 1522 |
|
|
2017
Q3 | USD 68.6 M | Vender |
1,820,278
-87,973
| -5% | -USD 2.86 M | 0.02% | 1063 |
|
|
2017
Q2 | USD 53.2 M | Comprar |
1,908,251
+785,352
| +70% | +USD 23.4 M | 0.01% | 1192 |
|
|
2017
Q1 | USD 38.6 M | Vender |
1,122,899
-421,359
| -27% | -USD 14.9 M | 0.01% | 1398 |
|
|
2016
Q4 | USD 44.5 M | Comprar |
1,544,258
+365,067
| +31% | +USD 9.7 M | 0.01% | 1356 |
|
|
2016
Q3 | USD 37.5 M | Comprar |
1,179,191
+846,830
| +255% | +USD 28.7 M | 0.01% | 1429 |
|
|
2016
Q2 | USD 10.8 M | Comprar |
332,361
+28,093
| +9% | +USD 940 k | ﹤0.01% | 2252 |
|
|
2016
Q1 | USD 8.51 M | Comprar |
304,268
+181,489
| +148% | +USD 3.96 M | ﹤0.01% | 2346 |
|
|
2015
Q4 | USD 4.38 M | Comprar |
122,779
+34,292
| +39% | +USD 1.21 M | ﹤0.01% | 2950 |
|
|
2015
Q3 | USD 2.93 M | Comprar |
88,487
+60,201
| +213% | +USD 2.5 M | ﹤0.01% | 3404 |
|
|
2015
Q2 | USD 1.18 M | Vender |
28,286
-21,696
| -43% | -USD 840 k | ﹤0.01% | 4385 |
|
|
2015
Q1 | USD 1.63 M | Comprar |
49,982
+9,970
| +25% | +USD 343 k | ﹤0.01% | 3983 |
|
|
2014
Q4 | USD 1.27 M | Vender |
40,012
-191,213
| -83% | -USD 5.42 M | ﹤0.01% | 4310 |
|
|
2014
Q3 | USD 5.72 M | Vender |
231,225
-169,022
| -42% | -USD 3.95 M | ﹤0.01% | 2871 |
|
|
2014
Q2 | USD 9.04 M | Comprar |
400,247
+102,567
| +34% | +USD 2.14 M | ﹤0.01% | 2456 |
|
|
2014
Q1 | USD 7.24 M | Vender |
297,680
-201,850
| -40% | -USD 5.11 M | ﹤0.01% | 2658 |
|
|
2013
Q4 | USD 12.5 M | Comprar |
499,530
+25,953
| +5% | +USD 612 k | ﹤0.01% | 2169 |
|
|
2013
Q3 | USD 13 M | Vender |
473,577
-85,070
| -15% | -USD 1.78 M | ﹤0.01% | 1980 |
|
|
2013
Q2 | USD 10.1 M | Comprar |
+558,647
| Nuevas | +USD 7.69 M | ﹤0.01% | 2079 |
|
Otros fondos que tienen ACAD en su cartera
BBA
Posición de Goldman Sachs en ACAD: resumen de T2 2026
Goldman Sachs aumentó su participación en Acadia Pharmaceuticals (ACAD) en 66% durante T2 2026, al comprar aproximadamente USD 22.5 M y elevar la posición a 2,580,115 acciones con un valor de USD 65.3 M. La posición representa 0.01% de la cartera y ocupa el puesto #1581.
Goldman Sachs reportó por primera vez una posición en ACAD en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. La posición alcanzó su máximo de USD 68.6 M en T3 2017. Al cierre de T2 2026, 354 fondos que sigue Wall St. Rank mantienen una posición en ACAD.
- Al cierre de T2 2026, Goldman Sachs tenía 2,580,115 acciones de Acadia Pharmaceuticals con un valor de USD 65.3 M.
- Goldman Sachs compró 1,022,311 acciones de Acadia Pharmaceuticals en T2 2026, por un monto estimado de USD 22.5 M.
- Acadia Pharmaceuticals representó 0.01% de la cartera de Goldman Sachs en T2 2026 y fue su posición número 1581.
- Goldman Sachs reportó por primera vez una posición en Acadia Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- La posición de Goldman Sachs en Acadia Pharmaceuticals alcanzó su máximo de USD 68.6 M en T3 2017.
- Al cierre de T2 2026, 354 fondos que sigue Wall St. Rank tenían Acadia Pharmaceuticals en cartera.
Según el Informe 13F de Goldman Sachs correspondiente a T2 2026, presentado el 14 ago 2026.